ArticleAnnals of clinical and translational neurology2026
Diffusion Basis Spectrum Imaging of Tissue Microstructure and Early Treatment in Multiple Sclerosis.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveConventional MRI cannot resolve the coexisting pathological processes within multiple sclerosis tissue. Diffusion Basis Spectrum Imaging decomposes the diffusion signal into fiber, cell, and hindered ratios indexing axonal integrity, cellularity, and extracellular space, respectively. We asked how these ratios differ between early relapsing and established non-relapsing disease, change with early treatment, and relate to disability, and secondarily, whether lesions form reproducible microstructural subtypes.
methodsThirty-seven participants underwent multi-shell diffusion MRI: 11 healthy controls, 15 treatment-naïve relapsing, and 11 non-relapsing patients. Thirteen were rescanned ~3 months after starting high-efficacy disease-modifying therapy. Metrics were extracted from normal-appearing gray and white matter and lesions (core, rim, and perilesional white matter); Gaussian mixture model clustering of per-lesion fiber, cell, and hindered ratios identified lesion subtypes.
resultsTreatment-naïve relapsing patients showed reduced normal-appearing white matter fiber (p = 0.04) and elevated hindered ratios (p = 0.02) versus controls. Lesions had lower fiber and cell ratios and higher hindered ratio than within-subject normal-appearing white matter (all p < 0.001). After treatment, lesional fiber ratio increased (p = 0.01) while lesional and gray matter cell ratios declined (both p = 0.02). Lesional cell ratio was higher in relapsing than non-relapsing patients at the core (p = 0.03) and rim (p = 0.04) but not perilesionally; treatment-related improvement was similar across compartments. Clustering yielded four reproducible subtypes (edematous-hypocellular, moderately cellular, actively inflamed, structurally preserved); the inflamed subtype predominated in relapsing and the edematous-hypocellular in non-relapsing disease.
interpretationDiffusion basis spectrum imaging distinguishes relapsing from non-relapsing disease by lesion-body cellularity and detects treatment-related changes in fiber and cell compartments. Reproducible, hypothesis-generating lesion subtypes support its use for in vivo lesion phenotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.